This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
by Sweta Killa
Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
HOOKIPA Pharma (HOOK) delivered earnings and revenue surprises of 45% and 105.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of -5.88% and 99.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
by Zacks Equity Research
Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark are included in this Analyst Blog.
5 Stocks That More Than Doubled in February
by Sweta Killa
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -12.60% and 19.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
by Sweta Killa
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium, Inc. (EQ) delivered earnings and revenue surprises of 47.37% and 6.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium, Inc. (EQ) delivered earnings and revenue surprises of 45% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)
by Zacks Equity Research
Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19
by Zacks Equity Research
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Is Equillium (EQ) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (EQ) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Equillium Gains From Positive Results on Coronavirus Drug
by Zacks Equity Research
Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.
Will Equillium Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Equillium.
Equillium Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Equillium has been struggling lately, but the selling pressure may be coming to an end soon.
Can The Uptrend Continue for Equillium?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Equillium
Equillium Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Equillium.